177Lu-FAPI-RGD

N/A

Report date: 2025/11/20 16:02:24

NME

Base Information

Drug Name177Lu-FAPI-RGD

Drug Alias Name177Lu-FAPI-RGD[177Lu]-FAPI-RGD

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionPositron-emission tomography enhancersIntegrin alpha-V/beta-3 antagonistsFibroblast activation protein alpha antagonists

TargetsIntegrin alpha-V/beta-3Prolyl endopeptidase FAP

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesPeking Union Medical College Hospital

China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College Hospital

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A